CASTLE BIOSCIENCES INC

NASDAQ: CSTL (Castle Biosciences, Inc.)

Last update: 17 Apr, 10:49AM

21.47

0.21 (0.99%)

Previous Close 21.26
Open 21.14
Volume 155,750
Avg. Volume (3M) 406,577
Market Cap 619,299,968
Price / Earnings (TTM) 34.63
Price / Sales 1.60
Price / Book 1.23
52 Weeks Range
16.97 (-20%) — 35.84 (66%)
Earnings Date 5 May 2025
Profit Margin -1.46%
Operating Margin (TTM) -31.74%
Diluted EPS (TTM) -0.190
Quarterly Revenue Growth (YOY) 20.60%
Total Debt/Equity (MRQ) 5.87%
Current Ratio (MRQ) 9.37
Operating Cash Flow (TTM) 65.67 M
Levered Free Cash Flow (TTM) 44.64 M
Return on Assets (TTM) -1.80%
Return on Equity (TTM) -1.20%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Bearish Bearish
Diagnostics & Research (Global) Bearish Bearish
Stock Castle Biosciences, Inc. Bearish Bullish

AIStockmoo Score

0.5
Analyst Consensus 3.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -1.0
Technical Oscillators 2.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CSTL 619 M - 34.63 1.23
SHC 4 B - 135.44 7.93
TWST 2 B - - 4.13
NEOG 1 B - - 0.450
CDNA 834 M - 13.39 2.87
BIAF 12 M - - 5.44

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Small Core
% Held by Insiders 2.98%
% Held by Institutions 93.01%
52 Weeks Range
16.97 (-20%) — 35.84 (66%)
Price Target Range
35.00 (63%) — 40.00 (86%)
High 40.00 (Scotiabank, 86.31%) Buy
Median 37.00 (72.33%)
Low 35.00 (Lake Street, 63.02%) Buy
Average 37.33 (73.87%)
Total 3 Buy
Avg. Price @ Call 16.42
Firm Date Target Price Call Price @ Call
Scotiabank 21 May 2025 40.00 (86.31%) Buy 16.02
Canaccord Genuity 06 May 2025 37.00 (72.33%) Buy 16.62
Lake Street 06 May 2025 35.00 (63.02%) Buy 16.62

No data within this time range.

Date Type Details
11 Jun 2025 Announcement Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
04 Jun 2025 Announcement Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
29 May 2025 Announcement New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
21 May 2025 Announcement Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
09 May 2025 Announcement Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
07 May 2025 Announcement Castle Biosciences Celebrates Skin Cancer Awareness Month
05 May 2025 Announcement Castle Biosciences Reports First Quarter 2025 Results
05 May 2025 Announcement Castle Biosciences to Acquire Previse
02 May 2025 Announcement New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
30 Apr 2025 Announcement New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
28 Apr 2025 Announcement DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
25 Apr 2025 Announcement New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
14 Apr 2025 Announcement Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
08 Apr 2025 Announcement Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
07 Apr 2025 Announcement Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
03 Apr 2025 Announcement Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
01 Apr 2025 Announcement Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
28 Mar 2025 Announcement Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria